Articolo pubblicato sul numero 130 de L’altra medicina magazine
COLESTEROLO: L’AFFARE DEL SECOLO
di Alberto Donzelli
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227-3337.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur H J 2020;41:111-188.
- Donzelli A, Giudicatti G, Duca P. Nuove linee guida europee sulla gestione delle dislipidemie: aggressività non giustificata dalle prove esistenti. E&P2020, 44 (4) luglio-agosto, 308-312.
- Vainshelboim B, Myers J. Dyslipidemia paradox: Analysis from the veterans exercise testing study. PLoS ONE 18(7):e0287923. https://doi.org/10.1371/journal.pone.0287923
- Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjold B, Hynes N, et al. Lack of an association
or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ open. 2016; 6(6):e010401.
- The Global Cardiovascular Risk Consortium. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023 Aug 26.DOI: 10.1056/NEJMoa2206916.
- Johannesen CDL, Langsted A, Mortensen MB, Nordestgaard BG. Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study. BMJ. 2020 Dec 8;371:m4266. doi: 10.1136/bmj.m4266. Erratum in: BMJ 2021 Feb 12;372:n422.
- Madsen CM, Varbo A, Tybjærg-Hansen A, et al. U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies, European Heart Journal 2018;39:1181–1190, https://doi.org/10.1093/eurheartj/ehx665
- Donzelli A, Battaggia A. The efficacy of ezetimibe does not seem a credible real effect. International Journal of Cardiology 2016; 222:795–796.
- Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664.
- van Bruggen FH, Luijendijk HJ. Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER. Am J Cardiovasc Drugs. 2022 Jan;22(1):5-8. doi: 10.1007/s40256-021-00480-y.
- Erviti J, Wright J, Bassett K, et al. Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data. BMJ Open. 2022 Dec 30;12(12):e060172. doi: 10.1136/bmjopen-2021-060172.
- Bays HE, Banach M, Catapano AL, et al. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. J Clin Lipidol 2020 Sep-Oct;14(5):649-59.e6. doi: 10.1016/j.jacl.2020.08.009.
- Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 2023 Mar 4. doi: 10.1056/NEJMoa2215024.
